Synuclein Meeting 2025

This week, our Research Director, Tom Briston will be attending the Synuclein Meeting 2025 in Cambridge (April 8-11).

This event brings together leading experts to explore the structure, physiology, and pathology of alpha-synuclein, as well as the latest developments in therapeutics and biomarkers for alpha-synucleinopathies.

At Harness Therapeutics, we're excited to engage with the latest research in this field, from fundamental discoveries to translational studies.

If you're heading to Cambridge's West Road Concert Hall, we'd love to connect. More information about the meeting is here.

#Synuclein2025 #HarnessTherapeutics #Biotech #AlphaSynuclein #ParkinsonsDisease #NeurodegenerativeDiseases

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

January 2025

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline

September 2024

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

View all